A new radioimmunoassay for urinary thromboxane B2 with prior purification by high performance liquid chromatography

Geoffroy, J; Benzoni, Daniel; Sassard, J

doi:10.1016/0262-1746(85)90072-1

Cited by 23 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urinary 6-keto-PGFla and TxB2 were determined using published methods (Benzoni et al 1982;Geoffroy et al 1985) which include an extraction followed by separation by high performance liquid chromatography and a specific immunoassay. Urinary 11dehydro-TxB2 was measured by a specific enzymoimmunoassay which includes an extraction on Sep-Pak columns and sample purification by thin-layer chromatography (Lellouche et al 1990).…”

Section: (Ii) Analytical Methodsmentioning

confidence: 99%

BLOOD PRESSURE EFFECTS OF THROMBOXANE A₂ BLOCKADE IN SPONTANEOUSLY HYPERTENSIVE RATS

Boussairi¹,

Sacquet²,

Benzoni³

et al. 1993

Clin Exp Pharma Physio

View full text Add to dashboard Cite

1. The effects of CGS 22652, a thromboxane (Tx) A2 synthase inhibitor and TxA2/prostaglandin (PG) H2 receptor antagonist, on blood pressure (BP) were studied in conscious freely moving spontaneously hypertensive rats (SHR). 2. Three groups of 13 male SHR were subcutaneously infused from 5 to 11 weeks of age via osmotic minipumps with CGS 22652 at doses of 5 (SHRa) or 10 (SHRb) mg/kg per 24 h or with the vehicle only (SHRc). A fourth group (SHRd, n = 13) was orally treated from 3 to 11 weeks of age with CGS 22652 (30 mg/kg) given by gavage once a day. 3. CGS 22652 dose-dependently reduced the age-related increase in systolic BP. The pressor response to noradrenaline (200 ng/kg, i.v.) but not to angiotensin I or II was slightly (P < 0.05) diminished in 11 week old SHRb and SHRd compared to SHRc. Acute ganglionic blockade by trimethaphan (10 mg/kg, i.v.), as well as angiotensin converting enzyme inhibition by perindopril (2 mg/kg, i.v.) decreased BP to a similar extent in the four groups. After combined blockade of vasopressin receptors and of the autonomic nervous system and the administration of a direct vasodilator (hydralazine, 3 mg/kg, i.v.), the residual mean BP was identical in the four groups of rats. 4. Chronic treatment with CGS 22652 dose-dependent antagonized the TxA2/PGH2 receptors but did not modify the TxA2 synthesis. The urinary sodium excretion did not differ between groups. 5. In conclusion, at the doses used, CGS 22652 given either orally or subcutaneously exhibited only TxA2/PGH2 receptor blocking properties in SHR.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: (Ii) Analytical Methodsmentioning

confidence: 99%

BLOOD PRESSURE EFFECTS OF THROMBOXANE A₂ BLOCKADE IN SPONTANEOUSLY HYPERTENSIVE RATS

Boussairi¹,

Sacquet²,

Benzoni³

et al. 1993

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…Urinary concentrations of 6 keto prostaglandin Fltc (6KPGF1,) and of thromboxane B2 (TxB2) the major stable metabolites of prostacyclin and thromboxane A2 respectively, were measured by specific radioimmunoassays after a high-performance liquid chromatographic separation step (Benzoni et al, 1982;Geoffroy et al, 1985).…”

Section: Methodsmentioning

confidence: 99%

Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids.

Ferry¹,

Geoffroy²,

Pozet³

et al. 1988

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The kinetics of a single oral dose (300 mg) of cicletanine a new antihypertensive drug with diuretic properties, and its effects on the urinary excretion of electrolytes and of the major stable metabolites of prostacyclin and thromboxane A2 were studied in patients with normal renal function (n = 6), mild (n = 9) and severe (n = 10) renal insufficiency. 2 In normotensive subjects with normal renal function, cicletanine was rapidly and regularly absorbed, its apparent elimination half-life established around 7 h, and both its renal clearance (0.4 ml min-') and its cumulative renal excretion (0.85% of the administered dose), were low. Mild renal insufficiency did not significantly alter these parameters, while severe renal impairment reduced the renal clearance and the cumulative urinary excretion of cicletanine and increased its apparent elimination half-life (31 h). However the area under the plasma curve was not changed due to reduced plasma concentrations in these patients. 3 Cicletanine induced a rapid and marked (four fold as a mean) increase in the urinary excretion of water, sodium and potassium which lasted for 6 to 10 h, in subjects with normal renal function. Renal insufficiency did not alter the slope of the calculated plasma concentration-effects curves but reduced the maximum effect observed for water, sodium and potassium. 4 A single oral dose of cicletanine did not change the urinary excretion of 6-ketoprostaglandin Fla and thromboxane B2 in the three groups of patients studied, the basal values of which being found to be closely related to the creatinine clearance. 5 It was concluded that i) from a pharmacokinetic view point, the dosage of cicletanine should only be slightly reduced in patients with a glomerular filtration rate below 30 ml min-', ii) as with most of the diuretic agents, its natriuretic properties were markedly decreased in these patients and iii) an alteration in the renal synthesis of prostacyclin or thromboxane seems unlikely to participate in the pharmacological effects of cicletanine.

show abstract

“…Immunological assays (radioimmunoassay or enzyme immunoassay) are the most widely used methods for qualitative/quantitative analysis of prostanoids. The main drawbacks of these assays are their lack of specificity for complex biological fluids such as plasma and urine [18], the trend to overestimate the levels of metabolites due to cross-reactivity, variability in the quantification of sequential samples, limitation to the detection of a single product at one time [19,20] and, in most cases, a commercial antibody is not available, particularly for new or unstable metabolites [21].…”

Section: Introductionmentioning

confidence: 99%

Automated method for targeting analysis of prostanoids in human serum by on-line solid-phase extraction and liquid chromatography–mass spectrometry in selected reaction monitoring

Ferreiro‐Vera

Mata-Granados

Priego-Capote

et al. 2011

Journal of Chromatography A

View full text Add to dashboard Cite

A new radioimmunoassay for urinary thromboxane B2 with prior purification by high performance liquid chromatography

Cited by 23 publications

References 12 publications

BLOOD PRESSURE EFFECTS OF THROMBOXANE A₂ BLOCKADE IN SPONTANEOUSLY HYPERTENSIVE RATS

BLOOD PRESSURE EFFECTS OF THROMBOXANE A₂ BLOCKADE IN SPONTANEOUSLY HYPERTENSIVE RATS

Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids.

Automated method for targeting analysis of prostanoids in human serum by on-line solid-phase extraction and liquid chromatography–mass spectrometry in selected reaction monitoring

Contact Info

Product

Resources

About

A new radioimmunoassay for urinary thromboxane B2 with prior purification by high performance liquid chromatography

Cited by 23 publications

References 12 publications

BLOOD PRESSURE EFFECTS OF THROMBOXANE A2 BLOCKADE IN SPONTANEOUSLY HYPERTENSIVE RATS

BLOOD PRESSURE EFFECTS OF THROMBOXANE A2 BLOCKADE IN SPONTANEOUSLY HYPERTENSIVE RATS

Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids.

Automated method for targeting analysis of prostanoids in human serum by on-line solid-phase extraction and liquid chromatography–mass spectrometry in selected reaction monitoring

Contact Info

Product

Resources

About

BLOOD PRESSURE EFFECTS OF THROMBOXANE A₂ BLOCKADE IN SPONTANEOUSLY HYPERTENSIVE RATS

BLOOD PRESSURE EFFECTS OF THROMBOXANE A₂ BLOCKADE IN SPONTANEOUSLY HYPERTENSIVE RATS